Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Terminated 1 enrolled M.D. Anderson Cancer Center Mirati Therapeutics Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Evaluate safety and tolerability, while establishing the recommended dose of the investigational drug combination of adagrasib and olaparib that can be given to participants with advanced solid tumor(s) with a KRAS G12C and/or KEAP1 mutation.

Timeline

Start: 2024-01-30
Primary completion: 2024-06-14
Completion: 2026-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adagrasib	Small molecule	—	Oral
Subject	Olaparib	Small molecule	—	Oral

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Summary

Timeline

Drugs

Indications